Anatomic Stage IIIA Breast Cancer AJCC v8 Active Not Recruiting Phase 2 Trials for Rifaximin (DB01220)

IndicationStatusPhase
DBCOND0109626 (Anatomic Stage IIIA Breast Cancer AJCC v8)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04249622Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast CancerTreatment